Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 798

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 4
Chunk 798
---
	24.64

			September 2027

			326,560

			$
			3.45

			October 2029

			934,590

The fair value of warrants issued during the year ended September 30, 2025 were estimated using the Black-Scholes option valuation model using the following assumptions:

			Year Ended September 30, 2025

			Class A Pref Share

			Risk free interest rate

			4.14
			%

			Expected life (years)

			5

			Expected share price volatility

			91.24
			%

			Expected dividend yield

			0.00
			%

F-17

EDESA BIOTECH, INC.

Notes to Consolidated Financial Statements

For the Years Ended September 30, 2025 and 2024

Share options

The Company adopted an Equity Incentive Compensation Plan in 2019 (the “2019 Plan”) administered by the independent members of the Board of Directors, which amended and restated prior plans. Options, restricted shares and restricted share units are eligible for grant under the 2019 Plan. The total number of shares available for issuance under the terms of the 2019 Plan is 2,367,737. The remaining number of shares available to grant at September 30, 2025 is 693,515.

The Company’s 2019 Plan allows options to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the option term is not to exceed 10 years and the exercise price of each option is determined by the independent members of the Board of Directors.

Options have been granted under the 2019 Plan allowing the holders to purchase common shares of the Company as follows:

			Number of Options

			Weighted Average Exercise Price

			Weighted Average Grant Date Fair Value

			Balance - September 30, 2023

			420,615

			$
			25.60

			$
			18.84

			Granted

			500

			4.10

			3.10

			Forfeited

			(2,401
			)

			15.00

			10.70

			Expired

			(35,674
			)

			33.18

			24.63